Clinical Trial

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after concurrent or sequential chemoradiotherapy. QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-17; most recent amendment 2025-02-07.
Trial Details
NCT Number NCT06789796
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Small-cell Lung Cancer
Enrollment 636 participants
Start Date 2025-02
Primary Completion 2028-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2025-02-11